Comparing Elicio Therapeutics (ELTX) & Its Rivals

Elicio Therapeutics (NASDAQ:ELTX) is one of 610 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its rivals? We will compare Elicio Therapeutics to similar companies based on the strength of its dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares Elicio Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-2,748.16%	-151.12%
Elicio Therapeutics Competitors	-809.33%	-698.34%	-27.95%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Elicio Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1	0	2	1	2.75
Elicio Therapeutics Competitors	8576	13260	40559	1399	2.55

Elicio Therapeutics presently has a consensus target price of $18.00, indicating a potential upside of 34.18%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 65.52%. Given Elicio Therapeutics’ rivals higher probable upside, analysts clearly believe Elicio Therapeutics has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Elicio Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Elicio Therapeutics	N/A	-$39.57 million	-5.59
Elicio Therapeutics Competitors	$903.00 million	$76.47 million	-28.78

Elicio Therapeutics’ rivals have higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 12.4% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Elicio Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Elicio Therapeutics’ rivals have a beta of 1.10, indicating that their average share price is 10% more volatile than the S&P 500.

Summary

Elicio Therapeutics rivals beat Elicio Therapeutics on 7 of the 13 factors compared.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.